Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Operating Leases (2019 - 2025)

Inmune Bio's Operating Leases history spans 7 years, with the latest figure at $623000.0 for Q3 2025.

  • For Q3 2025, Operating Leases changed N/A year-over-year to $623000.0; the TTM value through Sep 2025 reached $623000.0, changed N/A, while the annual FY2024 figure was $244000.0, 38.54% down from the prior year.
  • Operating Leases for Q3 2025 was $623000.0 at Inmune Bio, up from $231000.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $684000.0 in Q1 2022 and bottomed at $95000.0 in Q3 2021.
  • The 5-year median for Operating Leases is $360000.0 (2024), against an average of $390307.7.
  • The largest annual shift saw Operating Leases surged 538.95% in 2022 before it crashed 38.54% in 2024.
  • A 5-year view of Operating Leases shows it stood at $284000.0 in 2021, then surged by 115.85% to $613000.0 in 2022, then plummeted by 35.24% to $397000.0 in 2023, then tumbled by 38.54% to $244000.0 in 2024, then soared by 155.33% to $623000.0 in 2025.
  • Per Business Quant, the three most recent readings for INMB's Operating Leases are $623000.0 (Q3 2025), $231000.0 (Q2 2025), and $244000.0 (Q4 2024).